Novavax Stock News

Health officials see Novavax's protein-based vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna.

As a CNBC report recently pointed out, some publicly traded enterprises are standing out but for the wrong reasons. Feeling the pressure from the specter of an extended period of heightened borrowing

European Medicines Agency director Emer Cooke said on Thursday the agency expects to make a decision on Novavax's updated COVID vaccine in October.

Moderna and Novavax both are focused on the coronavirus vaccine market of the future. The two companies each are developing vaccine candidates to prevent coronavirus and flu.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

BA.2.86 is a new COVID variant health officials have been eyeing lately. But recent reports suggest that it may not be all that concerning.

Novavax was an early coronavirus vaccine favorite but fell behind and missed out on the biggest revenue opportunity. Now it may enter the fall vaccine market later than rivals Pfizer and Moderna.

Cases of COVID-19 are rising and providing a tailwind for Novavax's stock. However, the biotech's prospects in this market are hard to pin down.

Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months thr

Novavax, Inc. (NASDAQ:NVAX) shares recovered some lost ground in Tuesday premarket trading after slumping almost 13% on Monday after it missed out on US Food and Drug Administration (FDA) approval for

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.

Novavax once was a stock market winner, soaring in the early days of the coronavirus vaccine race. The company's vaccine reached the market behind rivals, and the stock price suffered.